Former CNET editor Dong Ngo has been involved with technology since 2000, starting with testing gadgets and writing code for CNET Labs' benchmarks. He managed CNET's San Francisco Labs, reviews 3D ...
Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows ...
Investigators at Memorial Sloan Kettering Cancer Center (MSK) have published results from a clinical trial that found people with recurrent multiple myeloma may benefit from receiving chimeric antigen ...
The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback